Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Status: Enrolling
Updated:  1/4/2016
University of Iowa Hospitals and Clinics
1557
mi
from 98109
Iowa City, IA
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Status: Enrolling
Updated: 1/4/2016
University of Iowa Hospitals and Clinics
1557
mi
from 98109
Iowa City, IA
Click here to add this to my saved trials
The Role of Vitamin D in Female Reproductive Tract Immunity
The Role of Vitamin D in Female Reproductive Tract Immunity
Status: Enrolling
Updated:  1/7/2016
Eastern Virginia Medical School CONRAD Clinical Research Center
2431
mi
from 98109
Norfolk, VA
The Role of Vitamin D in Female Reproductive Tract Immunity
The Role of Vitamin D in Female Reproductive Tract Immunity
Status: Enrolling
Updated: 1/7/2016
Eastern Virginia Medical School CONRAD Clinical Research Center
2431
mi
from 98109
Norfolk, VA
Click here to add this to my saved trials
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
The Role of Vitamin D and Quetiapine-induced Weight Gain
Status: Enrolling
Updated:  1/7/2016
Alegent Creighton Clinic - Psychiatric Associates (Dodge Street)
1367
mi
from 98109
Omaha, NE
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
The Role of Vitamin D and Quetiapine-induced Weight Gain
Status: Enrolling
Updated: 1/7/2016
Alegent Creighton Clinic - Psychiatric Associates (Dodge Street)
1367
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Three Different Programs of Paced Breathing in Treating Hot Flashes in Women
Paced Breathing for Hot Flashes: A Randomized Phase II Study
Status: Enrolling
Updated:  1/7/2016
Mayo Clinic Cancer Center
1450
mi
from 98109
Rochester, MN
Three Different Programs of Paced Breathing in Treating Hot Flashes in Women
Paced Breathing for Hot Flashes: A Randomized Phase II Study
Status: Enrolling
Updated: 1/7/2016
Mayo Clinic Cancer Center
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome
Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome
Status: Enrolling
Updated:  1/8/2016
Children's Hospital of Philadelphia
2373
mi
from 98109
Philadelphia, PA
Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome
Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome
Status: Enrolling
Updated: 1/8/2016
Children's Hospital of Philadelphia
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Multimodal Treatment Strategy for Cancer Cachexia
An Exploratory Trial of a Multimodal Treatment Strategy for Cancer Cachexia
Status: Enrolling
Updated:  1/8/2016
UT MD Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Multimodal Treatment Strategy for Cancer Cachexia
An Exploratory Trial of a Multimodal Treatment Strategy for Cancer Cachexia
Status: Enrolling
Updated: 1/8/2016
UT MD Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries
Hyperbaric Oxygen Radiation Tissue Injury Study - Project HORTIS
Status: Enrolling
Updated:  1/11/2016
Palmetto Health Richland
2319
mi
from 98109
Columbia, SC
Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries
Hyperbaric Oxygen Radiation Tissue Injury Study - Project HORTIS
Status: Enrolling
Updated: 1/11/2016
Palmetto Health Richland
2319
mi
from 98109
Columbia, SC
Click here to add this to my saved trials
Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries
Hyperbaric Oxygen Radiation Tissue Injury Study - Project HORTIS
Status: Enrolling
Updated:  1/11/2016
Wesley Medical Center
7361
mi
from 98109
Brisbane,
Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries
Hyperbaric Oxygen Radiation Tissue Injury Study - Project HORTIS
Status: Enrolling
Updated: 1/11/2016
Wesley Medical Center
7361
mi
from 98109
Brisbane,
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Advanced Medical Specialties
2729
mi
from 98109
Miami, FL
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Advanced Medical Specialties
2729
mi
from 98109
Miami, FL
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Bay Area Cancer Research Dept.ofBayAreaCancerResearch
667
mi
from 98109
Concord, CA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Bay Area Cancer Research Dept.ofBayAreaCancerResearch
667
mi
from 98109
Concord, CA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Baylor Research Institute Baylor Research Institute (17)
1681
mi
from 98109
Dallas, TX
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Baylor Research Institute Baylor Research Institute (17)
1681
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Cancer Center of Kansas
1435
mi
from 98109
Witchita, KA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Cancer Center of Kansas
1435
mi
from 98109
Witchita, KA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Cancer Centers of the Carolinas Cancer Center
2224
mi
from 98109
Greenville, SC
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Cancer Centers of the Carolinas Cancer Center
2224
mi
from 98109
Greenville, SC
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Duke University Medical Center Duke University Med Ctr
2341
mi
from 98109
Durham, NC
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Duke University Medical Center Duke University Med Ctr
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Georgia Regents University MedCollege of GA Cancer Ctr 2
2300
mi
from 98109
Augusta, GA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Georgia Regents University MedCollege of GA Cancer Ctr 2
2300
mi
from 98109
Augusta, GA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Hackensack University Medical Center Dept.of HackensackUniv.MedCtr.
2394
mi
from 98109
Hackensack, NJ
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Hackensack University Medical Center Dept.of HackensackUniv.MedCtr.
2394
mi
from 98109
Hackensack, NJ
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Henry Ford Hospital
1930
mi
from 98109
Detroit, MI
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Henry Ford Hospital
1930
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Indiana Blood and Marrow Institute
1810
mi
from 98109
Beach Grove, IN
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Indiana Blood and Marrow Institute
1810
mi
from 98109
Beach Grove, IN
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Louis A. Weiss Memorial Hospital
1728
mi
from 98109
Chicago, IL
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Louis A. Weiss Memorial Hospital
1728
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center(3)
2099
mi
from 98109
New Orleans, LA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center(3)
2099
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Millennium Oncology
1874
mi
from 98109
Houston, TX
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Millennium Oncology
1874
mi
from 98109
Houston, TX
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Montefiore Medical Center
2402
mi
from 98109
Bronx, NY
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Montefiore Medical Center
2402
mi
from 98109
Bronx, NY
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Oncology Consultants Oncology Consultants, P.A.
1890
mi
from 98109
Houston, TX
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Oncology Consultants Oncology Consultants, P.A.
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Oregon Health and Science University
147
mi
from 98109
Portland, OR
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Oregon Health and Science University
147
mi
from 98109
Portland, OR
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Pacific Cancer Medical Center
979
mi
from 98109
Anaheim, CA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Pacific Cancer Medical Center
979
mi
from 98109
Anaheim, CA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Providence Regional Cancer Partnership
25
mi
from 98109
Everett, WA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Providence Regional Cancer Partnership
25
mi
from 98109
Everett, WA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer
952
mi
from 98109
Burbank, CA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer
952
mi
from 98109
Burbank, CA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
St. Jude Heritage Medical Group Virginia Crosson Cancer Center
978
mi
from 98109
Yorba Linda, CA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
St. Jude Heritage Medical Group Virginia Crosson Cancer Center
978
mi
from 98109
Yorba Linda, CA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
St. Louis University Cancer Center
1720
mi
from 98109
St. Louis, MO
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
St. Louis University Cancer Center
1720
mi
from 98109
St. Louis, MO
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Stroger Cook County Hospital Division of Hematology & Onc
1733
mi
from 98109
Chicago, IL
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Stroger Cook County Hospital Division of Hematology & Onc
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Tennessee Oncology Sarah Cannon Research Inst.
1971
mi
from 98109
Nashville, TN
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Tennessee Oncology Sarah Cannon Research Inst.
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
The Jones Clinic, PC
1877
mi
from 98109
Germantown, TN
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
The Jones Clinic, PC
1877
mi
from 98109
Germantown, TN
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
University of Nebraska Medical Center University of Nebraska Med Ctr
1366
mi
from 98109
Omaha, NE
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
University of Nebraska Medical Center University of Nebraska Med Ctr
1366
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
University of Virginia
2283
mi
from 98109
Charlottesville, VA
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
University of Virginia
2283
mi
from 98109
Charlottesville, VA
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Sarah Cannon Research Institute SCRI
2452
mi
from 98109
Jacksonville, FL
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Sarah Cannon Research Institute SCRI
2452
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Pasco Hernando Oncology
2501
mi
from 98109
New Port Richey, FL
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Pasco Hernando Oncology
2501
mi
from 98109
New Port Richey, FL
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
University of Maryland
2327
mi
from 98109
Baltimore, MD
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
University of Maryland
2327
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
University of Rochester Medical Ct James P Wilmot Cancer Ctr
2161
mi
from 98109
Rochester, NY
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
University of Rochester Medical Ct James P Wilmot Cancer Ctr
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated:  1/11/2016
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
2085
mi
from 98109
Chattanooga, TN
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Status: Enrolling
Updated: 1/11/2016
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
2085
mi
from 98109
Chattanooga, TN
Click here to add this to my saved trials
Evaluating Vitamin D Content in Mushrooms
Evaluation of Vitamin D in a Mushroom Supplement
Status: Enrolling
Updated:  1/11/2016
Boston Med Ctr
2485
mi
from 98109
Boston, MA
Evaluating Vitamin D Content in Mushrooms
Evaluation of Vitamin D in a Mushroom Supplement
Status: Enrolling
Updated: 1/11/2016
Boston Med Ctr
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery
Ultraviolet Light and Vitamin D in Subjects With Fat Malabsorption or After Gastric Bypass Surgery
Status: Enrolling
Updated:  1/11/2016
Boston Med Ctr
2485
mi
from 98109
Boston, MA
Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery
Ultraviolet Light and Vitamin D in Subjects With Fat Malabsorption or After Gastric Bypass Surgery
Status: Enrolling
Updated: 1/11/2016
Boston Med Ctr
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults
A Randomized, Placebo-Controlled Pilot Trial Assessing Two Doses of N-Acetylcysteine on Changes in Oxidative Stress and Endothelial Function in HIV-infected Older Adults Receiving Stable Antiretroviral Therapy
Status: Enrolling
Updated:  1/11/2016
Indiana University Health University Hospital, Indiana Clinical Research Center
1867
mi
from 98109
Indianapolis, IN
N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults
A Randomized, Placebo-Controlled Pilot Trial Assessing Two Doses of N-Acetylcysteine on Changes in Oxidative Stress and Endothelial Function in HIV-infected Older Adults Receiving Stable Antiretroviral Therapy
Status: Enrolling
Updated: 1/11/2016
Indiana University Health University Hospital, Indiana Clinical Research Center
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Early or Late Foley Removal After Thoracotomy
Optimal Timing of Foley Catheter Removal in Patients Undergoing Thoracic Surgery With Epidural Analgesia: A Randomized, Controlled Trial
Status: Enrolling
Updated:  1/12/2016
Mayo Clinic Rochester
1450
mi
from 98109
Rochester, MN
Early or Late Foley Removal After Thoracotomy
Optimal Timing of Foley Catheter Removal in Patients Undergoing Thoracic Surgery With Epidural Analgesia: A Randomized, Controlled Trial
Status: Enrolling
Updated: 1/12/2016
Mayo Clinic Rochester
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D
Status: Enrolling
Updated:  1/13/2016
Stratton VA Medical Center
2351
mi
from 98109
Albany, NY
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D
Status: Enrolling
Updated: 1/13/2016
Stratton VA Medical Center
2351
mi
from 98109
Albany, NY
Click here to add this to my saved trials
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D
Status: Enrolling
Updated:  1/13/2016
Hortense and Louis Rubin Dialysis Center
2346
mi
from 98109
Clifton Park, NY
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D
Status: Enrolling
Updated: 1/13/2016
Hortense and Louis Rubin Dialysis Center
2346
mi
from 98109
Clifton Park, NY
Click here to add this to my saved trials
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D
Status: Enrolling
Updated:  1/13/2016
Hortense and Louis Rubin Dialysis Center
2339
mi
from 98109
Saratoga Springs, NY
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D
Status: Enrolling
Updated: 1/13/2016
Hortense and Louis Rubin Dialysis Center
2339
mi
from 98109
Saratoga Springs, NY
Click here to add this to my saved trials
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D
Status: Enrolling
Updated:  1/13/2016
Hortense and Louis Rubin Dialysis Center
2353
mi
from 98109
Troy, NY
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D
Status: Enrolling
Updated: 1/13/2016
Hortense and Louis Rubin Dialysis Center
2353
mi
from 98109
Troy, NY
Click here to add this to my saved trials
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
Status: Enrolling
Updated:  1/18/2016
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
Status: Enrolling
Updated: 1/18/2016
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated:  1/18/2016
UCD Telehealth Network - Lake Almanor Clinic
509
mi
from 98109
Chester, CA
Mexiletine for the Treatment of Muscle Cramps in ALS
Mexiletine for the Treatment of Muscle Cramps in ALS
Status: Enrolling
Updated: 1/18/2016
UCD Telehealth Network - Lake Almanor Clinic
509
mi
from 98109
Chester, CA
Click here to add this to my saved trials